sellWeak cluster of 5
Jama Pitman sold $17k of DCPH
See Remarks at Deciphera Pharmaceuticals, Inc.. 1,407 shares at an average of $12.02, traded Oct 30, 2023, filed Oct 31, 2023.
Warning score
30Value
$17k
1,407 shares
Holdings after
48,283
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$17k at market
- 0Share of holdings soldSold 2.8% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-053938, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2023 | AGrant or award Common Stock | +5,576 | - | - | 49,690 | Oct 31, 2023 |
| Oct 30, 2023 | SOpen-market sale Common Stock | -1,407 | $12.02 | $17k | 48,283 | Oct 31, 2023 |
Related signals
Other insiders at Deciphera Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Deciphera Pharmaceuticals, Inc. | Jama Pitman SVP, Chief Development Officer | $35k 2,267 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $41k 2,615 shares | -2% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $35k 2,267 shares | -4% | |
| 43Moderate | Deciphera Pharmaceuticals, Inc. | Thomas Patrick Kelly Chief Financial Officer | $47k 3,010 shares | -4% | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $23k 1,624 shares | -3% | |
| 43Moderate | Deciphera Pharmaceuticals, Inc. | Thomas Patrick Kelly Chief Financial Officer | $35k 2,435 shares | -4% | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | Jama Pitman SVP, Chief Development Officer | $23k 1,624 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $35k 2,435 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $43k 2,792 shares | -3% | |
| 35Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $27k 1,727 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.